Market Overview

The Durvalumab market is predicted to develop at a compound annual growth rate (CAGR) of xx% from 2024 to 2034, when it is projected to reach USD xx Billion, based on an average growth pattern. The market is estimated to reach a value of USD xx Billion in 2024.

SOURCE: We Market Research

An immunotherapy medication called durvalumab targets the PD-L1 protein on cancer cells. Durvalumab works by inhibiting this protein, which makes it easier for the immune system to identify and eliminate cancer cells. It is used to treat a variety of malignancies, such as bladder cancer and non-small cell lung cancer. By stopping cancer cells from eluding immune surveillance, the medication strengthens the body's innate defenses against the illness. Durvalumab is usually given intravenously as part of a more comprehensive cancer treatment plan that also includes supportive care and other medicines.

The rising prevalence of diseases including bladder cancer and non-small cell lung cancer, which raises the need for efficient therapies, is what propels the worldwide durvalumab market. Durvalumab's popularity is increased by developments in immunotherapy and positive clinical trials proving its effectiveness. Market expansion is further supported by continuous R&D expenditures and regulatory approvals for extended uses. Durvalumab's acceptance is also fueled by increased healthcare spending as well as increased patient and provider knowledge of cutting-edge treatments. All of these elements work together to support the expanding market for this immunotherapy medication.

Market Scope

Durvalumab Industry: Dynamics & Restrains

Market opportunity:

We Market Research: Durvalumab Dashboard

Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.

Durvalumab Segmentation

Market- By Indication Analysis

By Indication, the Durvalumab Market is Categories into Non-Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma, Other Cancers. The Non-Small Cell Lung Cancer (NSCLC) segment accounts for the largest share of around 68% in 2024.

NSCLC is driven by the rising incidence of lung cancer, advances in immunotherapy, positive clinical outcomes, regulatory approvals, and growing awareness leading to early diagnosis, all enhancing its adoption in treating NSCLC.

The following segments are part of an in-depth analysis of the global Durvalumab market:

Durvalumab Industry: Regional Analysis

North America Market Forecast

North America dominates the Durvalumab Market with the highest revenue generating market with share of more than 48%. The North American Durvalumab market benefits from high adoption of innovative cancer therapies, supported by extensive insurance coverage that ensures patient access. Strong R&D investment by major pharmaceutical companies and a robust healthcare infrastructure enable quick uptake of new treatments. Additionally, the U.S. FDA’s efficient regulatory processes facilitate rapid market entry and adoption for various cancer indications.

Europe Market Statistics

In Europe, the Durvalumab market is driven by a rising cancer burden and an aging population, both of which increase demand for advanced treatments. The region's well-established healthcare systems and the presence of leading pharmaceutical companies foster market growth. EMA approvals facilitate widespread use, though varying reimbursement policies across countries impact market access and expansion differently.

Asia Pacific Market Forecasts

Asia Pacific is expected to be the fastest-growing regional segment of the Durvalumab market during the forecast period. The Asia-Pacific region is experiencing rapid market growth due to economic development, which boosts healthcare spending and infrastructure improvements. The rising incidence of cancer across the region increases demand for Durvalumab. Additionally, expanding access to advanced treatments in countries like China, Japan, and India, along with evolving regulatory frameworks, enhances market opportunities and accelerates growth.

Key Market Players

The Durvalumab Market is dominated by a few large companies, such as

·         Medimmune (AstraZeneca)   

1.      Global Durvalumab Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Durvalumab Market Scope and Market Estimation

1.2.1. Global Durvalumab Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)

1.2.2. Global Durvalumab Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034

1.3.    Market Segmentation

1.3.1. Indication of Global Durvalumab Market

1.3.2. End User of Global Durvalumab Market

1.3.3. Distribution Channel of Global Durvalumab Market

1.3.4. Region of Global Durvalumab Market

2.      Executive Summary

2.1.    Market Dynamics

2.1.1. Drivers

2.1.2. Limitations

2.1.3. Opportunities

2.1.4. Impact Analysis of Drivers and Restraints

2.2.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.3.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.4.    Porter’s Five Forces Analysis

2.4.1. Bargaining Power of Suppliers

2.4.2. Bargaining Power of Buyers

2.4.3. Threat of Substitutes

2.4.4. Threat of New Entrants

2.4.5. Competitive Rivalry

2.5.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Durvalumab Market Estimates & Historical Trend Analysis (2019 - 2023)

4.      Global Durvalumab Market Estimates & Forecast Trend Analysis, by Indication

4.1.    Global Durvalumab Market Revenue (US$ Mn) Estimates and Forecasts, by Indication, 2019 to 2034

4.1.1. Non-Small Cell Lung Cancer (NSCLC)

4.1.2. Urothelial Carcinoma

4.1.3. Other Cancers

5.      Global Durvalumab Market Estimates & Forecast Trend Analysis, by End User

5.1.    Global Durvalumab Market Revenue (US$ Mn) Estimates and Forecasts, by End User, 2019 to 2034

5.1.1. Hospitals

5.1.2. Specialty Clinics

5.1.3. Cancer Research Institutes

5.1.4. Others

6.      Global Durvalumab Market Estimates & Forecast Trend Analysis, by Distribution Channel

6.1.    Global Durvalumab Market Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channel, 2019 to 2034

6.1.1. Direct Sales

6.1.2. Distributors

6.1.3. Online Pharmacies

7.      Global Durvalumab Market Estimates & Forecast Trend Analysis, by Region

7.1.    Global Durvalumab Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034

7.1.1. North America

7.1.2. Europe

7.1.3. Asia Pacific

7.1.4. Middle East & Africa

7.1.5. South America

8.      North America Durvalumab Market: Estimates & Forecast Trend Analysis

8.1.    North America Durvalumab Market Assessments & Key Findings

8.1.1. North America Durvalumab Market Introduction

8.1.2. North America Durvalumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

8.1.2.1.   By Indication

8.1.2.2.   By End User

8.1.2.3.   By Distribution Channel

8.1.2.4.   By Country

8.1.2.4.1.     The U.S.

8.1.2.4.2.     Canada

8.1.2.4.3.     Mexico

9.      Europe Durvalumab Market: Estimates & Forecast Trend Analysis

9.1.    Europe Durvalumab Market Assessments & Key Findings

9.1.1. Europe Durvalumab Market Introduction

9.1.2. Europe Durvalumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

9.1.2.1.   By Indication

9.1.2.2.   By End User

9.1.2.3.   By Distribution Channel

9.1.2.4.        By Country

9.1.2.4.1.     Germany

9.1.2.4.2.     U.K.

9.1.2.4.3.     France

9.1.2.4.4.     Italy

9.1.2.4.5.     Spain

9.1.2.4.6.     Russia

9.1.2.4.7.     Rest of Europe

10.  Asia Pacific Durvalumab Market: Estimates & Forecast Trend Analysis

10.1.  Asia Pacific Market Assessments & Key Findings

10.1.1.   Asia Pacific Durvalumab Market Introduction

10.1.2.   Asia Pacific Durvalumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

10.1.2.1.    By Indication

10.1.2.2.    By End User

10.1.2.3.    By Distribution Channel

10.1.2.4.    By Country

10.1.2.4.1. China

10.1.2.4.2. Japan

10.1.2.4.3. India

10.1.2.4.4. Australia

10.1.2.4.5. South Korea

10.1.2.4.6. ASEAN

10.1.2.4.7. Rest of Asia Pacific

11.  Middle East & Africa Durvalumab Market: Estimates & Forecast Trend Analysis

11.1.  Middle East & Africa Market Assessments & Key Findings

11.1.1.   Middle East & Africa Durvalumab Market Introduction

11.1.2.   Middle East & Africa Durvalumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

11.1.2.1.    By Indication

11.1.2.2.    By End User

11.1.2.3.    By Distribution Channel

11.1.2.4.    By Country

11.1.2.4.1. U.A.E.

11.1.2.4.2. Saudi Arabia

11.1.2.4.3. Egypt

11.1.2.4.4. South Africa

11.1.2.4.5. Rest of Middle East & Africa

12.  South America Durvalumab Market: Estimates & Forecast Trend Analysis

12.1.  South America Market Assessments & Key Findings

12.1.1.   South America Durvalumab Market Introduction

12.1.2.   South America Durvalumab Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

12.1.2.1.    By Indication

12.1.2.2.    By End User

12.1.2.3.    By Distribution Channel

12.1.2.4.    By Country

12.1.2.4.1. Brazil

12.1.2.4.2. Argentina

12.1.2.4.3. Colombia

12.1.2.4.4. Rest of South America

13.  Competition Landscape

13.1.  Global Durvalumab Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

13.2.  Global Durvalumab Market Competition White Space Analysis, By End-user

13.3.  Global Durvalumab Market Competition Heat Map Analysis, By End-user

13.4.  Global Durvalumab Market Concentration & Company Market Shares (%) Analysis, 2022

14.  Company Profiles

14.1.                     Medimmune (AstraZeneca).

14.1.1.   Company Overview & Key Stats

14.1.2.   Financial Performance & KPIs

14.1.3.   Product Portfolio

14.1.4.   Business Strategy & Recent Developments

15.  Research Methodology

15.1.  External Transportations / Databases

15.2.  Internal Proprietary Database

15.3.  Primary Research

15.4.  Secondary Research

15.5.  Assumptions

15.6.  Limitations

15.7.  Report FAQs

16.  Research Findings & Conclusion